Sage Therapeutics (NASDAQ:SAGE – Get Free Report) is scheduled to release its earnings data after the market closes on Tuesday, October 29th. Analysts expect Sage Therapeutics to post earnings of ($1.53) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.68) by ($0.02). Sage Therapeutics had a negative net margin of 458.30% and a negative return on equity of 55.87%. The business had revenue of $8.65 million during the quarter, compared to analysts’ expectations of $8.85 million. During the same quarter in the previous year, the business posted ($2.68) EPS. The company’s quarterly revenue was up 249.8% on a year-over-year basis. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Sage Therapeutics Stock Performance
NASDAQ SAGE opened at $8.01 on Monday. Sage Therapeutics has a one year low of $5.84 and a one year high of $28.26. The company’s 50 day moving average price is $7.53 and its 200 day moving average price is $10.10. The firm has a market capitalization of $482.06 million, a price-to-earnings ratio of -0.95 and a beta of 0.91.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on Sage Therapeutics
Sage Therapeutics Company Profile
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Featured Articles
- Five stocks we like better than Sage Therapeutics
- There Are Different Types of Stock To Invest In
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What Are Trending Stocks? Trending Stocks Explained
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Invest in the Best Canadian StocksÂ
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.